for people ages 45-85 (full criteria)
Healthy Volunteers
healthy people welcome
at San Francisco, California and other locations
study started
completion around



The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.


Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this prospective multi-center observational study is to validate a blood-based test for the detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a routine screening colonoscopy.


Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases, Colon Lesion, Colon Polyp, Colorectal Cancer, Polyp, Adenoma, Rectal Diseases, Gastrointestinal Tract Cancers, Artificial Intelligence, Liquid Biopsy, Blood Test Cancer, Cancer Diagnostic, Genomics, Genomics Test, CRC, Cancer Screening, Cancer Early Detection Test, Screening, Colonoscopy, Machine Learning, Freenome Test, Colorectal Cancer (CRC), Colorectal Cancer Screening, Colorectal Neoplasms, Colonic Neoplasms, Gastrointestinal Neoplasms, Colonic Diseases, Polyps


You can join if…

Open to people ages 45-85

  1. 45-85 years of age
  2. Willing to undergo a standard-of-care screening colonoscopy
  3. Able and willing to provide a blood sample
  4. Able and willing to sign informed consent

You CAN'T join if...

  1. Known hereditary gastrointestinal cancer syndrome (for example, hereditary non-polyposis CRC syndrome (HNPCC) or Lynch syndrome, or familial adenomatous polyposis (FAP)
  2. Personal history 2.1 CRC or colorectal adenoma 2.2 Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and crohn's disease (CD) 2.3 Colonoscopy in the 9 years preceding enrollment 2.4 Stool DNA testing in the 2 years preceding enrollment 2.5 Symptoms of lower gastrointestinal tract disease warranting colonoscopic evaluation
  3. A medical condition which, in the opinion of the Investigator, should preclude enrollment in the study
  4. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days up to and including the date of providing informed consent or may be administered through the time of the colonoscopy


  • UCSF Mount Zion Medical Center
    San Francisco California 94115 United States
  • East Bay Center for Digestive Health
    Oakland California 94612 United States
  • Kaiser Permanente Northern California
    Walnut Creek California 94596 United States
  • Clinical Research of California LLC
    Walnut Creek California 94598 United States


in progress, not accepting new patients
Start Date
Completion Date
Freenome Holdings Inc.
Study Type
Expecting 50000 study participants
Last Updated